The epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib (TarcevaTM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: Interim results of a phase II trial Meeting Abstract
| Authors: | Patel, J.; Miller, V.; Kris, M.; Shah, N.; Tyson, L.; Pizzo, B.; Zakowski, M.; Cespon, M.; Heelan, R.; Johnson, D. |
| Abstract Title: | The epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib (TarcevaTM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: Interim results of a phase II trial |
| Meeting Title: | 12th European Cancer Conference (ECCO 12) |
| Keywords: | smoking status |
| Journal Title: | EJC Supplements |
| Volume: | 1 |
| Issue: | 5 |
| Meeting Dates: | 2003 Sep 21-25 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 1359-6349 |
| Publisher: | Pergamon-Elsevier Science Ltd |
| Date Published: | 2003-09-01 |
| Start Page: | S21 |
| Language: | English |
| ACCESSION: | BCI:BCI200400097572 |
| DOI: | 10.1016/s1359-6349(03)90089-9 |
| PROVIDER: | biosis |
| Notes: | Meeting Abstract: 54 -- 12th ECCO (European Cancer Conference) -- Copenhagen, Denmark -- September 21-25, 2003 -- Federation of European Cancer Societies -- Source: Biosis |
